Dna Key Stage 3

[Holly Coffell]

Youshould have this in your Report library. Navigate to Menu > Reports > Reports and click Reports library on the upper right. Search for "Deal time spent in each stage". (I had to filter the report library by deals first, using the sidebar, and scroll down a bit. The search doesn't work properly for me.)

@RPopovich , @PPlant4 Im not sure about the out of the box report but it's very easy to build yourself using either single object och custom report builder.

Since a couple months ago there were new properties created as default called "cumulative time spent in "deal stage X""

@Jwyoung It only comes in a summarized data table view - so you can only see average time numbers summarized based on a date property. I was looking for data split into individual deals but had no luck.

Enhancing cross-border payments is a G20 priority during the Saudi Arabian Presidency. Faster, cheaper, more transparent and more inclusive cross-border payment services, including remittances, would have widespread benefits for citizens and economies worldwide, supporting economic growth, international trade, global development and financial inclusion.

Enhancing cross-border payments requires addressing frictions in existing cross-border payment processes. These frictions include: fragmented data standards or lack of interoperability; complexities in meeting compliance requirements, including for anti-money laundering and countering the financing of terrorism (AML/CFT), and data protection purposes; different operating hours across different time zones; and outdated legacy technology platforms. A number of public sector initiatives have sought to address these challenges and frictions by enhancing existing payment arrangements.

Financial innovation is creating opportunities to make payments more efficient. Technological innovation could build on existing cross-border and domestic payment arrangements or take the form of new structures and ecosystems. However, the use of new technologies and business models in cross-border payments also involves challenges and risks.

Global cross-border payments are carried out through a diverse multi-layered set of networks. A roadmap for enhancing cross-border payments, therefore, will need to encompass a variety of approaches and time horizons. Some building blocks that form part of the roadmap, which may be shorter-term actions, should benefit a number of different types of existing arrangements. Other building blocks, which may be more medium-term, may go beyond adjustments to existing arrangements by proposing actions that should eventually improve the structure of the system.

Assessment (Stage 1): In this report the FSB, in coordination with relevant international organisations and standard-setting bodies has assessed existing arrangements and challenges. The report is being submitted to G20 Finance Ministers and Central Bank Governors ahead of their virtual meeting next week, together with a technical background report providing further details.

Building Blocks (Stage 2): The Committee on Payments and Market Infrastructures (CPMI) is leading the work on creating building blocks of a response to improve the current global cross-border payment arrangements. This will set out areas where further public sector work could assist in moving to an improved cross-border payments system and in public goods or removing unnecessary barriers, and accordingly provide an update to the G20 in July 2020.

Roadmap (Stage 3): Building on the previous stages, the FSB will coordinate, with CPMI and other relevant international organisations and standard-setting bodies, the development of a roadmap to pave the way forward. In particular, the FSB will report to the G20 on practical steps and indicative timeframes needed to do so. The three-stage process will be submitted as a combined report to the G20 in October 2020.

The report concludes with some preliminary thoughts on areas to consider when developing the eventual roadmap, which will include practical steps and indicative timeframes. These include questions to explore a range of topics that fall under four broad categories: operational improvement of payment infrastructures; standardisation of data and market practice; legal, regulatory and oversight framework; and progress monitoring and information sharing.

Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.

Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:

For most types of cancer, doctors need to know how much cancer there is and where it is (among other things) to help determine the best treatment options. For example, the best treatment for an early-stage cancer may be surgery or radiation, while a more advanced-stage cancer may need treatments that reach all parts of the body, such as chemotherapy, targeted drug therapy, or immunotherapy.

The clinical stage is an estimate of the extent of the cancer based on results of physical exams, imaging tests (x-rays, CT scans, etc.), endoscopy exams, and any biopsies that are done before treatment starts. For some cancers, the results of other tests, such as blood tests, are also used in clinical staging.

If surgery to remove the cancer is the first treatment, doctors can also determine the pathological stage (also called the surgical stage). The pathological stage relies on the results of the exams and tests done before the surgery, as well as what is learned about the cancer during surgery.

Sometimes, the pathological stage is different from the clinical stage (for instance, if the surgery shows the cancer has spread more than was seen on imaging tests). The pathological stage gives more precise information, which can be used to help determine what other treatments might be needed, as well as to help predict treatment response and outcomes (prognosis).

Staging might also be done again at some point if the cancer comes back (recurs) or progresses (grows or spreads without ever having gone away completely). This information can be used to help guide decisions about further treatment.

When a cancer is staged again after the initial staging, it is sometimes referred to as restaging. Often the same tests that were done when the cancer was first diagnosed (such as physical exams, imaging tests, endoscopy exams, biopsies, and maybe surgery) are done again.

The American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) maintain the TNM classification system as a way for doctors to stage many different types of cancer based on certain common standards.

Lymph nodes near the primary tumor usually are checked to find out if cancer has spread into them. Lymph nodes are small, bean-shaped collections of immune cells. Many types of cancer often spread to nearby lymph nodes before they reach other parts of the body.

Grade: For most cancers, the grade is a measure of how abnormal the cancer cells look under the microscope. This is also called differentiation. Grade can be important because cancers with more abnormal-looking cells tend to grow and spread faster.

Cell type: Cancers in some parts of the body can start in different types of cells. Because the type of cancer cell can affect treatment and outlook, it can be a factor in staging. For example, cancers of the esophagus are mainly either squamous cell cancers or adenocarcinomas. Squamous cell esophageal cancers are staged differently from esophageal adenocarcinomas.

Blood levels of tumor markers: For some cancers, the blood levels of certain substances (called tumor markers or biomarkers) can affect the stage of the cancer. For example, in prostate cancer, the level of prostate-specific antigen (PSA) in the blood is taken into account in assigning a stage.

Results of tests on the cancer cells: For some cancers, lab tests done on the cancer cells are an important part of staging. For example, in breast cancer, the stage can be affected by whether or not the cancer cells have proteins called hormone receptors on them.

For most cancers, the stage is a Roman numeral from I (1) to IV (4). Stage I cancers are less advanced and often have a better prognosis (outlook). Higher stage cancers typically have spread farther (or have other concerning features), so they might require more intense (or different kinds of) treatment. Sometimes stages are subdivided as well, using capital letters (for example, stage III might be subdivided into stages IIIA and IIIB).

For many types of cancer, prognosis is often expressed as a survival rate. This is the percentage of people with a certain type and stage of cancer who are still alive a certain amount of time (usually 5 years) after being diagnosed. For example, if the 5-year survival rate for a certain type and stage of cancer is 80%, it means that 80 out of 100 people who have that type and stage of cancer will still be expected to be alive after 5 years.

3a8082e126